Navigation Links
Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009
Date:5/5/2009

NANJING, China, May 6 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today that it intends to release its 2009 first quarter results on Monday, May 18, 2009, after the market closes in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2009 first quarter results on Tuesday, March 19, at 8 a.m. ET (Tuesday, March 19, at 8 p.m. Beijing/Hong Kong time).

    To access the conference call, please dial:

     United States toll-free dial-in number:  +1.800.659.2056
     International dial-in number:            +1.617.614.2714
     North China toll-free dial-in number:    10.800.152.1490
     South China toll-free dial-in number:    10.800.130.0399
     Hong Kong dial-in number:                +852.3002.1672

Please ask to be connected to Simcere's Q1 2009 earnings call and provide the following passcode: 25770430. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at http://www.simcere.com .

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free dial-in number: +1.888.286.8010

     International dial-in number:            +1.617.801.6888

The passcode for replay participants is: 21293840. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR; Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
7. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
8. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
9. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
10. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
11. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Yorba Linda, Ca (PRWEB) , ... May 25, ... ... essential to truly understanding the full process behind each occurrence. Live cell imaging ... , In this webinar, the use of automated fluorescence microscopy methods will be ...
(Date:5/24/2017)... ... May 24, 2017 , ... Today, the South Davis Sewer ... Biological Nutrient Recovery (ABNRâ„¢) technology at its 4,000,000 gallon per day South Plant. ... sustainably meet current and future nutrient discharge regulations. The ABNR platform, which is ...
(Date:5/24/2017)... 2017 (PRWEB) , ... May 24, 2017 , ... ... Medical systems are increasingly being developed with Wi-Fi connectivity to reduce the amount ... from room to room. In addition, compact mobile devices including infusion pumps, heart ...
(Date:5/23/2017)... ... May 23, 2017 , ... A recent survey conducted by the Weed Science ... control weed in 12 categories of broadleaf crops, fruits and vegetables, while common lambsquarters ... U.S. and Canada participated in the 2016 survey, the second conducted by WSSA. ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
Breaking Biology News(10 mins):